On March 19, 2022, Voyager Therapeutics, Inc. (the “Company”) and Alfred Sandrock, M.D., Ph.D. entered into an employment agreement (the “Sandrock Agreement”) pursuant to which Dr. Sandrock agreed to serve as the President of the Company, effective on March 22, 2022 (the “Commencement Date”). In accordance with the Sandrock Agreement, the Company and Dr. Sandrock terminated the consulting agreement the parties entered into in February 2022 pursuant to which Dr. Sandrock was providing advisory services to the Company. Dr. Sandrock continues to serve as a director on the Board of Directors of the Company (the “Board”) and as a member of both the Executive Committee and the Science and Technology Committee of the Board.

Dr. Sandrock, age 64, was appointed to the Board in February 2022. From February 1998 to December 2021, Dr. Sandrock served in positions of increasing responsibility at Biogen Inc. On the Commencement Date, in connection with the appointment of Dr. Sandrock, Michael Higgins ceased to serve as Interim President of the Company. Mr. Higgins continues to serve as Chairman of the Board and, effective as of the Commencement Date, is considered an independent director in accordance with the rules of the Nasdaq Stock Market.

Mr. Higgins also continues to serve as Chair of the Executive Committee of the Board.